Merck says COVID-19 pill cuts hospitalization, death risk by 30%
Merck & Co Inc said on Friday its experimental COVID-19 pill reduced the risk of hospitalization and death by 30% in a study, according to data from all the patients enrolled in a late-stage study.
On October 1, Merck said its pill lowered the chance of hospitalization or death by about 50% in patients at risk for severe illness given the treatment within five days of onset. Merck did not provide figures regarding patients getting the pill within three days of onset.
Merck’s pill, developed with Ridgeback Biotherapeutics, is a nucleoside analog with a mechanism of action that aims to introduce errors into the genetic code of the virus. Because the drug generates random mutations into the virus, it is difficult for the coronavirus to evolve and become resistant.
EU watchdog could approve Merck COVID-19 pill ‘within weeks’
US FDA advisers to review Merck’s oral COVID-19 drug next month
Be careful in using COVID-19 drug molnupiravir, infectious disease expert warns
Subscribe to our daily newsletter
The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link .
Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.